| 25 May 2026 |
Oxytocin Acetate |
9.2 |
2mg |
2.1mg |
+4.9% |
99.02% |
Lab B |
| 25 May 2026 |
Vesugen |
7.2 |
20mg |
20.8mg |
+3.8% |
96.60% |
Lab A |
| 24 May 2026 |
4-Piperidone CAS 41661-47-6 |
6.5 |
1g |
1.2g |
+19.3% |
98.98% |
Lab G |
| 24 May 2026 |
AHK-CU |
6.3 |
30mg |
33.6mg |
+12.0% |
98.30% |
Lab D |
| 24 May 2026 |
AHK-CU |
5.4 |
10mg |
9.3mg |
-7.1% |
98.74% |
Lab A |
| 24 May 2026 |
MGF |
10.0 |
50mg |
54.3mg |
+8.6% |
97.59% |
Lab D |
| 24 May 2026 |
Prostamax |
4.3 |
20mg |
17.3mg |
-13.6% |
95.65% |
Lab A |
| 24 May 2026 |
Prostamax |
4.3 |
50mg |
51.0mg |
+2.0% |
97.50% |
Lab E |
| 24 May 2026 |
BPC157 5mg + TB500 5mg Blend |
6.9 |
20mg |
19.4mg |
-3.2% |
96.21% |
Lab F |
| 24 May 2026 |
GW-501516 (Cardarine) Raw |
6.1 |
100g |
85.9g |
-14.1% |
96.77% |
Lab E |
| 24 May 2026 |
Propionyl chloride CAS 79-03-8 |
5.5 |
1g |
1.2g |
+22.0% |
97.76% |
Lab C |
| 24 May 2026 |
Semax |
10.0 |
2mg |
1.8mg |
-7.8% |
97.65% |
Lab A |
| 24 May 2026 |
1-Boc-4-(2-fluorophenylamino)piperidine CAS 887583-57-5 |
7.1 |
10g |
9.0g |
-10.0% |
95.63% |
Lab D |
| 24 May 2026 |
4-Anilinopiperidine CAS 99918-43-1 |
7.2 |
500g |
515.0g |
+3.0% |
96.92% |
Lab B |
| 24 May 2026 |
Crystagen |
6.5 |
2mg |
1.9mg |
-2.8% |
97.08% |
Lab E |
| 24 May 2026 |
Ostarine (MK-2866) |
8.7 |
20mg |
21.9mg |
+9.6% |
95.29% |
Lab F |
| 24 May 2026 |
Primobolan Oral (Methenolone Acetate) |
8.5 |
50mg |
55.8mg |
+11.6% |
99.21% |
Lab A |
| 23 May 2026 |
Lipo Mino Mix (B6+Methionine+Inositol+Choline+B1+B2+Carnitine) |
4.9 |
300mg/ml |
363.0mg/ml |
+21.0% |
95.80% |
Lab F |
| 23 May 2026 |
P21 |
6.2 |
50mg |
46.8mg |
-6.4% |
96.14% |
Lab D |
| 23 May 2026 |
Tesamorelin 11mg + Ipamorelin 6mg Blend |
6.1 |
2mg |
2.0mg |
+1.8% |
96.88% |
Lab A |
| 21 May 2026 |
4-Anilinopiperidine CAS 99918-43-1 |
9.8 |
1g |
1.1g |
+13.3% |
97.58% |
Lab A |
| 21 May 2026 |
Cagrilintide 5mg + Semaglutide 5mg Blend |
6.1 |
10mg |
8.7mg |
-13.4% |
99.82% |
Lab A |
| 21 May 2026 |
CJC-1295 w/o DAC 10mg + IPA 10mg Blend |
9.4 |
50mg |
61.8mg |
+23.5% |
97.80% |
Lab F |
| 21 May 2026 |
DHB (1-Test Cyp) Oral |
4.9 |
25mg |
30.7mg |
+22.9% |
95.95% |
Lab D |
| 21 May 2026 |
P21 |
6.4 |
30mg |
27.0mg |
-10.0% |
98.91% |
Lab C |
| 21 May 2026 |
BMK glycidic acid (P-2-P methyl glycidic acid / sodium salt) CAS 5449-12-7 |
7.3 |
1g |
1.1g |
+11.3% |
98.05% |
Lab F |
| 21 May 2026 |
PE 22-28 |
5.4 |
30mg |
30.9mg |
+3.0% |
98.36% |
Lab F |
| 20 May 2026 |
Crystagen |
6.0 |
2mg |
2.1mg |
+5.7% |
99.26% |
Lab E |
| 19 May 2026 |
Letrozole |
7.0 |
20mg |
20.0mg |
+0.2% |
99.90% |
Lab C |
| 19 May 2026 |
Methylamine (base) CAS 74-89-5 |
7.5 |
5g |
4.9g |
-2.4% |
98.73% |
Lab A |
| 17 May 2026 |
AICAR |
4.2 |
10mg |
11.7mg |
+17.1% |
98.65% |
Lab A |
| 17 May 2026 |
Enclomiphene |
7.2 |
50mg |
55.4mg |
+10.8% |
95.28% |
Lab E |
| 29 Jan 2026 |
Clenbuterol |
5.4 |
20mg |
19.9mg |
-0.7% |
95.55% |
Lab G |
| 26 Jan 2026 |
Cerebrolysin |
5.9 |
5mg |
6.2mg |
+24.9% |
96.61% |
Lab D |
| 26 Jan 2026 |
DHB (1-Test Cyp) Oral |
8.2 |
50mg |
56.1mg |
+12.2% |
95.68% |
Lab B |
| 26 Jan 2026 |
Enclomiphene |
5.6 |
20mg |
23.7mg |
+18.7% |
97.63% |
Lab G |
| 19 Jan 2026 |
1-Boc-4-(2-fluorophenylamino)piperidine CAS 887583-57-5 |
6.4 |
1g |
1.2g |
+24.4% |
97.17% |
Lab G |
| 19 Jan 2026 |
CJC-1295 With DAC |
4.7 |
5mg |
5.3mg |
+5.6% |
99.61% |
Lab D |
| 19 Jan 2026 |
Methylamine (base) CAS 74-89-5 |
6.2 |
1g |
0.9g |
-9.0% |
98.95% |
Lab E |
| 9 Jan 2026 |
Dianabol |
7.9 |
100mg |
87.4mg |
-12.6% |
96.36% |
Lab A |
| 7 Jan 2026 |
Enclomiphene |
9.1 |
50mg |
58.6mg |
+17.3% |
98.68% |
Lab A |
| 7 Jan 2026 |
NAD+ |
9.1 |
5mg |
6.1mg |
+22.2% |
98.14% |
Lab A |
| 6 Jan 2026 |
CJC-1295 With DAC |
6.4 |
20mg |
22.4mg |
+11.8% |
95.53% |
Lab E |
| 6 Jan 2026 |
Clenbuterol |
7.3 |
10mg |
10.4mg |
+4.2% |
96.98% |
Lab D |
| 29 Dec 2025 |
BPC-157 |
|
7.8 |
10mg |
(no batch claim) |
11.4mg |
11-18-25 |
| 16 Dec 2025 |
Retatrutide |
|
9.5 |
15mg |
(no batch claim) |
15.6mg |
PC-G2-RT15 |
| 12 Dec 2025 |
GLOW GHK-CU 50mg+TB500 10mg+BPC157 10mg |
9.6 |
15mg |
13.3mg |
-11.0% |
97.16% |
Lab D |
| 12 Dec 2025 |
Ostarine (MK-2866) |
10.0 |
25mg |
24.8mg |
-0.9% |
99.08% |
Lab D |
| 5 Dec 2025 |
Finasteride |
6.5 |
25mg |
28.3mg |
+13.3% |
95.58% |
Lab D |
| 5 Dec 2025 |
HMG |
4.0 |
30mg |
26.1mg |
-13.1% |
99.08% |
Lab G |
| 23 Nov 2025 |
AHK-CU |
5.0 |
2mg |
2.1mg |
+3.8% |
98.54% |
Lab C |
| 23 Nov 2025 |
Dianabol |
5.7 |
50mg |
56.5mg |
+12.9% |
98.84% |
Lab F |
| 23 Nov 2025 |
Letrozole |
5.8 |
50mg |
53.4mg |
+6.7% |
98.17% |
Lab F |
| 17 Nov 2025 |
Cagrilintide 5mg + Semaglutide 5mg Blend |
7.4 |
2mg |
2.4mg |
+20.6% |
98.98% |
Lab E |
| 14 Nov 2025 |
4-Piperidone CAS 41661-47-6 |
8.9 |
10g |
11.0g |
+9.9% |
98.81% |
Lab F |
| 14 Nov 2025 |
Clenbuterol |
5.8 |
20mg |
20.1mg |
+0.7% |
99.40% |
Lab C |
| 14 Nov 2025 |
SS-31 |
5.2 |
50mg |
45.1mg |
-9.8% |
97.58% |
Lab C |
| 5 Nov 2025 |
Letrozole |
7.8 |
20mg |
21.7mg |
+8.5% |
96.78% |
Lab B |
| 5 Nov 2025 |
Oxytocin Acetate |
7.5 |
30mg |
28.2mg |
-5.8% |
96.17% |
Lab A |
| 5 Nov 2025 |
PE 22-28 |
8.2 |
50mg |
48.2mg |
-3.6% |
96.50% |
Lab F |
| 5 Nov 2025 |
Vesugen |
6.5 |
5mg |
5.1mg |
+2.5% |
97.07% |
Lab E |
| 4 Nov 2025 |
Methylamine hydrochloride CAS 593-51-1 |
10.0 |
100g |
102.0g |
+2.0% |
97.74% |
Lab C |
| 4 Nov 2025 |
Vesugen |
6.8 |
15mg |
15.3mg |
+1.8% |
95.97% |
Lab B |
| 17 Oct 2025 |
BMK glycidic acid (P-2-P methyl glycidic acid / sodium salt) CAS 5449-12-7 |
7.4 |
500g |
472.4g |
-5.5% |
97.67% |
Lab D |
| 9 Oct 2025 |
CJC-1295 With DAC |
5.4 |
50mg |
58.9mg |
+17.9% |
96.39% |
Lab D |
| 9 Oct 2025 |
NAD+ |
7.7 |
10mg |
12.0mg |
+20.1% |
98.90% |
Lab F |
| 3 Oct 2025 |
BPC157 5mg + TB500 5mg Blend |
6.9 |
50mg |
52.2mg |
+4.5% |
97.38% |
Lab D |
| 20 Mar 2025 |
BPC-157 |
|
5.0 |
10mg |
11.7mgwebsite |
13.75mg |
PC-Z1-BP10 |
| 20 Mar 2025 |
Melanotan II |
|
4.7 |
10mg |
13.0mgwebsite |
8.18mg |
PC-Z-MT210 |
| 20 Mar 2025 |
CJC-1295 |
DAC |
5.3 |
5mg |
5.2mgwebsite |
4.84mg |
PC-Z-CJCDAC |
| 20 Mar 2025 |
Semaglutide |
|
8.9 |
15mg |
16.2mgwebsite |
16.76mg |
PC-J-S15 |
| 20 Mar 2025 |
Ipamorelin |
|
6.6 |
10mg |
13.0mgwebsite |
14.8mg |
PC-Z1-IP10 |